Fed Circuit refuses to hear $23m Medtronic loss
The US Court of Appeals for the Federal Circuit has rejected Medtronic’s attempt to revisit a ruling that lumbered the medical device company with a $23 million loss.
Eli Lilly secures victory before Federal Circuit
The US Court of Appeals for the Federal Circuit affirmed a series of Patent Trial and Appeal Board inter partes reviews, which upheld a patent owned by Eli Lilly late last week.
LSPN 19: Humira litigation may prompt more antitrust scrutiny
The six antitrust class-action lawsuits that have been brought against AbbVie could result in more scrutiny of settlement agreements between the innovator and the biosimilar manufacturer, with potential antitrust complications.
LSPN 19: Courts need to revisit patentability of diagnostic tests
US courts need to revisit the patentability of diagnostic tests under section 101, according to Memorial Sloan Kettering Cancer Center’s chief IP counsel.
LSPN 19: Two bites at the apple here to stay, says Alkermes director
Petitioners will continue to be able to launch litigation simultaneously before both the district court and the Patent Trial and Appeal Board, effectively having two bites at the apple, according to John Kirkland, director of IP at biopharmaceutical company Alkermes.
LSPN 19: Mayo has led us down the rabbit hole, says lawyer
There’s alarm in the scientific community because of how broadly the principles of the Mayo test for section 101 are being used to strike down patents on profound innovations and discoveries.
Indian court clears export of patented Bayer drugs for research
The Delhi High Court has cleared two Indian drug companies to export a cancer drug and blood thinner, both patented by Bayer, for the purposes of development and clinical trials for regulatory clearances.
Companies file amicus brief opposing Athena ruling
Biotech and pharmaceutical companies have submitted an amicus brief urging an appeals court to rethink a ruling, which invalidated a patent exclusively licensed by Athena Diagnostics.
Eli Lilly enters $35m immunology R&D deal
Eli Lilly has entered into a $35m global licensing and research agreement with biotech company Avidity Biosciences.
Insurer accuses Janssen of sham lawsuits to stop cancer generic
A US health insurance provider is suing a subsidiary of Johnson & Johnson for filing “sham” patent litigation in a bid to stop generic forms of a prostate cancer treatment from entering the market.
